The long-acting injectable shaping the future of HIV therapy
Bibliographic record
Abstract
Cabotegravir/rilpivirine (Cabenuva®) gained approval by Health Canada, the US Food and Drug Administration, and the European Commission in 2021 as the first long-acting injectable for HIV-1 treatment in virally supressed adults. A long-acting formulation of cabotegravir (Apretude®) subsequently showed promise when trialled as an option for HIV prevention in adults and adolescents, offering an alternative to the well-established daily pre-exposure prophylaxis (PrEP) regimen. For HIV treatment, cabotegravir/rilpivirine has been approved for those aged 12 and older, although insufficient evidence currently exists to support its use in pregnancy. Cabotegravir/rilpivirine is the first long-acting injectable medication approved for HIV treatment and prophylaxis, available to virally suppressed adults and adolescent patients with no history of treatment failure. The incorporation of long-acting injectables into standard HIV care is expected to mitigate some of the non-adherence issues with daily oral HIV regimens by demanding fewer lifestyle adjustments, and by enhancing patient confidentiality through infrequent dose administrations. Despite barriers to achieving global access, long-acting injectables have the potential to dampen further transmission, and to simplify treatment options for patients who are already affected by HIV. Efforts are under way to expand the reach of cabotegravir to low- and middle-income countries to maximise the impact of long-acting injectables on reducing HIV transmission worldwide
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.009 | 0.010 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.001 | 0.004 |
| Scholarly communication | 0.007 | 0.006 |
| Open science | 0.001 | 0.003 |
| Research integrity | 0.004 | 0.008 |
| Insufficient payload (model declined to judge) | 0.013 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".